Group 1 - The company Xianju Pharmaceutical announced a cash dividend distribution plan for the first half of 2025, proposing a payment of 1.00 RMB per 10 shares to all shareholders [1] - The total number of shares used as the basis for the dividend distribution is 989,204,866 shares [1] - The record date for the dividend is set for October 21, 2025, and the ex-dividend date is October 22, 2025 [1]

3、本次实施的利润分配方案与公司 2025 年第二次临时股东大会审议通过 的分配方案一致。 4、本次实施的利润分配方案距公司 2025 年第二次临时股东大会审议通过 的时间未超过两个月。 二、本次权益分派方案 股票代码：002332 股票简称：仙琚制药 公告编号：2025-044 浙江仙琚制药股份有限公司 2025 年半年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 浙江仙琚制药股份有限公司（以下简称"公司"或"本公司"）2025 年半 年度权益分派方案已获 2025 年 9 月 19 日召开的公司 2025 年第二次临时股东大 会审议通过，现将权益分派事宜公告如下： 一、 股东大会审议通过权益分派方案情况 1、2025 年 9 月 19 日，公司 2025 年第二次临时股东大会审议通过《关于 2025 年半年度利润分配的预案》：以 2025 年 6 月 30 日的总股本 989,204,866 股 为基数，向全体股东每 10 股派发现金红利人民币 1.00 元（含税）。 2、公司 2025 年半年度利润分配方案以固定总额的方式分配，分配 ...

Core Viewpoint - Zhejiang Xianju Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the consistency evaluation of the quality and efficacy of its Acetate Dexamethasone Tablets, which enhances the company's market competitiveness [1][2]. Group 1: Drug Information - The company has successfully passed the consistency evaluation for the 0.5mg specification of Acetate Dexamethasone Tablets, with the drug approval number being Guoyao Zhunzi H20258221 [2]. - The 0.75mg specification of Acetate Dexamethasone Tablets was previously approved in August 2025 [2]. - Acetate Dexamethasone Tablets are corticosteroids primarily used for allergic and autoimmune inflammatory diseases, including connective tissue diseases, severe bronchial asthma, dermatitis, ulcerative colitis, acute leukemia, and malignant lymphoma [1]. Group 2: Regulatory and Approval Process - The approval was based on the Drug Administration Law of the People's Republic of China and relevant government opinions on the reform of drug and medical device review and approval systems [1]. - The product adheres to the national drug registration standards YBH26782025 set by the National Medical Products Administration [2]. Group 3: Company Impact - The approval of the 0.5mg specification is expected to strengthen and enhance the product's market competitiveness and provide valuable experience for future drug consistency evaluations [2].

Core Points - The company, Xianju Pharmaceutical, has received approval from the National Medical Products Administration for a supplemental application regarding Dexamethasone Acetate Tablets [2] - The newly approved specification for Dexamethasone Acetate Tablets has passed the consistency evaluation of quality and efficacy for generic drugs [2] Company Summary - Xianju Pharmaceutical is now authorized to market a new specification of Dexamethasone Acetate Tablets, which enhances its product portfolio [2] - The approval signifies the company's commitment to maintaining high standards in drug quality and efficacy [2]

Core Viewpoint - Xianju Pharmaceutical (002332.SZ) has received approval from the National Medical Products Administration for a supplemental application regarding Acetate Dexamethasone Tablets, which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1: Product Approval - The company has obtained a notification for the approval of Acetate Dexamethasone Tablets, indicating regulatory compliance and potential market expansion [1] - The new specification of Acetate Dexamethasone Tablets enhances the product portfolio of the company [1] Group 2: Product Indications - Acetate Dexamethasone Tablets are classified as corticosteroids and are primarily used for allergic and autoimmune inflammatory diseases [1] - Indications include connective tissue diseases, severe bronchial asthma, dermatitis, ulcerative colitis, acute leukemia, and malignant lymphoma [1]

证券代码：002332 证券简称：仙琚制药 公告编号：2025-043 浙江仙琚制药股份有限公司 关于醋酸地塞米松片新增规格通过一致性评价的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 浙江仙琚制药股份有限公司（以下简称"公司"）于近日收到国家药品 监督管理局核准签发的关于醋酸地塞米松片的《药品补充申请批准通知书》 （通知书编号：2025B04681），公司醋酸地塞米松片新增规格通过仿制药质 量和疗效一致性评价。现将相关情况公告如下： 1 药品名称 剂型 规格 药品注册 标准编号 注册分类 药品生产 企业 醋酸地塞米松片 片剂 0.5mg YBH26782025 化学药品 浙江仙琚制药股 份有限公司 一、药品基本信息 0.5mg，药品批准文号为：国药准字H20258221，目前产品执行标准为国家药 品监督管理局药品注册标准YBH26782025。 三、对公司的影响及风险提示 公司醋酸地塞米松片0.5mg规格通过仿制药质量和疗效一致性评价，有利 于巩固和提升产品市场竞争力，为公司后续药品一致性评价工作积累经验。 申请内容：申报仿制药质量和疗效一致性评价。 ...

Group 1 - The core viewpoint of the article highlights the growth in China's chemical pharmaceutical raw material production, with a reported output of 329,000 tons in May 2025, reflecting a year-on-year increase of 3.8% [1] - Cumulative production of chemical pharmaceutical raw materials from January to May 2025 reached 1,585,000 tons, showing a cumulative growth of 5% [1] - The article references a report by Zhiyan Consulting, which provides insights into the market supply and demand trends in the Chinese chemical pharmaceutical industry from 2025 to 2031 [1] Group 2 - The listed companies in the article include Heng Rui Medicine, East China Medicine, Li Zhu Group, Baiyunshan, North China Pharmaceutical, Hai Zheng Pharmaceutical, Fosun Pharmaceutical, Ke Lun Pharmaceutical, En Hua Pharmaceutical, and Xian Ju Pharmaceutical [1] - Zhiyan Consulting is described as a leading industry consulting firm in China, specializing in in-depth industry research reports, business plans, feasibility studies, and customized services [1] - The article emphasizes Zhiyan Consulting's commitment to providing comprehensive industry solutions to empower investment decisions through professional insights and market acumen [1]

Core Points - Zhejiang Xianju Pharmaceutical Co., Ltd. has received an administrative regulatory measure from the China Securities Regulatory Commission due to issues related to the management and use of raised funds [1][2] - The company has previously faced penalties for price monopoly related to the raw material dexamethasone phosphate sodium [5][6] Fund Management Issues - The Zhejiang Securities Regulatory Bureau found that Xianju Pharmaceutical had not followed proper procedures for the review and disclosure of certain raised funds, used raised funds for unrelated expenses, and mixed raised funds with its own funds when purchasing structured deposit financial products [2][3] Regulatory Actions - The regulatory measures include warning letters issued to the company and key personnel, including the chairman, general manager, financial director, and board secretary, which will be recorded in the securities and futures market integrity archives [3] Impact on Operations - Xianju Pharmaceutical stated that the administrative regulatory measures will not affect its normal production and business activities, and the company will comply with legal and regulatory requirements for timely information disclosure [4] Previous Penalties - Earlier in the year, Xianju Pharmaceutical was fined a total of 195 million yuan for engaging in price-fixing agreements that violated anti-monopoly laws, with the fine amounting to 4.88% of the company's audited revenue and 49.17% of its net profit attributable to shareholders for 2024 [5][6] Financial Performance - The company has experienced a decline in revenue and net profit in recent years, with revenues of 4.123 billion yuan and 4.001 billion yuan for 2023 and 2024, respectively, representing year-on-year declines of 5.85% and 2.98% [7] - In the first half of 2025, the company reported revenues of 1.869 billion yuan, a year-on-year decrease of 12.56%, with net profit attributable to shareholders at 308 million yuan, down 9.26% [7]

证券代码：002332 证券简称：仙琚制药 公告编号：2025-040 浙江仙琚制药股份有限公司 关于公司及相关人员收到浙江证监局 警示函的公告 登录新浪财经APP 搜索【信披】查看更多考评等级 浙江仙琚制药股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 浙江仙琚制药股份有限公司（以下简称"公司"）于近日收到中国证券监督管理委员会浙江监管局（以下 简称"浙江证监局"）出具的行政监管措施决定书《关于对浙江仙琚制药股份有限公司及相关人员采取出 具警示函措施的决定》〔2025〕210号）（以下简称"《决定书》"）。现将相关情况公告如下： 一、《决定书》的主要内容 浙江证监局在现场检查中发现浙江仙琚制药股份有限公司（以下简称公司）募集资金管理和使用方面存 在以下问题:部分募集资金置换未按规定履行审议程序并披露，使用募集资金支付与募投项目无关的部 分费用，使用闲置募集资金购买银行结构性存款理财产品时存在募集资金与自有资金混同的情形。 公司上述行为违反了《上市公司信息披露管理办法》(证监会令第182号)第三条第一款，《上市公司监 管指引第2号--上市公司募集 ...

Core Points - The company, Xianju Pharmaceutical, has received approval from the National Medical Products Administration for the registration of Estradiol Tablets [2] Group 1 - The approval includes the issuance of a Drug Registration Certificate with the number 2025S02904 [2]